A US$2-million, 8-year attempt to replicate influential preclinical cancer research papers has released its final — and disquieting — results. Fewer than half of the experiments assessed stood up to scrutiny, reports the Reproducibility Project: Cancer Biology (RPCB) team in eLife1,2. The project — one of the most robust reproducibility studies performed so far — documented how hurdles including vague research protocols and uncooperative authors delayed the initiative by five years and halved its scope.
“These results aren’t surprising. And, simultaneously, they’re shocking,” says Brian Nosek, an RPCB investigator and executive director of the Center for Open Science in Charlottesville, Virginia. Although initially planning to repeat 193 experiments from 53 papers, the team ran just 50 experiments from 23 papers.
https://www.nature.com/articles/d41586-021-03691-0 [nature.com]